Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3663338 | 0.84 | IGF1R (0.56) | IGF1RMEN1KMT2A | |
| SCHEMBL598053 | 0.83 | IGF1R (0.48) | IGF1RPTGS1PTGS2MAPTNPC1 | |
| SCHEMBL598052 | 0.83 | IGF1R (0.48) | IGF1RPTGS1PTGS2MAPTNPC1 | |
| SCHEMBL57809 | 0.80 | IGF1R (0.74) | IGF1R | |
| SCHEMBL654797 | 0.76 | LMNA (0.44) | IGF1RPTGS1PTGS2MAPTNPC1 | |
| SCHEMBL1101872 | 0.75 | PLK4 (0.47) | IGF1RMAPTRAB9AMEN1KMT2A | |
| SCHEMBL58060 | 0.74 | PTGS1 (0.42) | IGF1RPTGS1PTGS2MAPTNPC1 | |
| SCHEMBL22411350 | 0.73 | KMT2A (0.47) | IGF1RMAPTNPC1RAB9AMEN1 | |
| SCHEMBL14524709 | 0.73 | PTGS1 (0.39) | IGF1RPTGS1PTGS2MAPTNPC1 | |
| SCHEMBL166734 | 0.72 | ALDH1A1 (0.41) | IGF1RPTGS1PTGS2MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928456-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS INC (US) | 2015-04-22 | — | — | EP | disclosed |
| EP-1928456-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-8114870-B2 | Method of treating disease states using substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114870-B2 | Method of treating disease states using substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090264422-A1 | METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264422-A1 | METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-7563787-B2 | Substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563787-B2 | Substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20070142368-A1 | Substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142368-A1 | Substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142368-A1 | Substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. | 2007-06-21 | — | — | US | disclosed |
| WO-2007041358-A2 | SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142368-A1 | Substituted pyrazole compounds | AURKC, AURKA, AURKB | IGF1R 2112/4885PTGS1 4269/4885PTGS2 3605/4885 |
| US-20090264422-A1 | METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS | AURKC, AURKA, AURKB | IGF1R 2564/4885PTGS1 3634/4885PTGS2 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.